Stoke Therapeutics, a preclinical biotech developing RNA-targeted therapies for rare genetic diseases, announced terms for its IPO on Friday.
The Bedford, MA-based company plans to raise $101 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Stoke Therapeutics would command a fully diluted market value of $509 million.
Stoke Therapeutics was founded in 2014 and plans to list on the Nasdaq under the symbol STOK. J.P. Morgan, Cowen and Credit Suisse are the joint bookrunners on the deal. It is expected to price June 18, 2019.
